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Surveillance Bias in Cancer Risk 
After Unrelated Medical Conditions: 
Example Urolithiasis
Kari Hemminki1,2, Otto Hemminki3,4, Asta Försti1,2, Kristina Sundquist2, Jan Sundquist2,5 & 
Xinjun Li2
We analysed cancer risks in patients with urinary tract stones but some features of the generated results 
alarmed us about possible surveillance bias, which we describe in this report. We used nationwide 
Swedish hospital records to identify patients with urinary tract stones (N = 211,718) and cancer 
registration data for cancer patients for years 1987 to 2012. Standardized incidence ratios (SIRs) for 
cancer were calculated after the last medical contact for urinary tract stones. All cancers were increased 
after kidney (SIR 1.54, 95%CI: 1.50–1.58), ureter (1.44, 1.42–1.47), mixed (1.51, 1.44–1.58) and bladder 
stones (1.63, 1.57–1.70). The risk of kidney cancer was increased most of all cancers after kidney, ureter 
and mixed stones while bladder cancer was increased most after bladder stones. All SIRs decreased 
steeply in the course of follow-up time. Tumour sizes were smaller in kidney cancer and in situ colon 
cancers were more common in patients diagnosed after urinary tract stones compared to all patients. 
The results suggest that surveillance bias influenced the result which somewhat surprisingly appeared 
to extend past 10 years of follow-up and include cancers at distant anatomical sites. Surveillance bias 
may be difficult to avoid in the present type of observational studies in clinical settings.
Surveillance bias is a type of information bias which occurs when one group of subjects is followed up more 
closely than others, for example, if they undergo medical treatment1, 2. The term is often used synonymously with 
detection bias, particularly, if the bias is due to the use of a particular diagnostic technique or type of equipment. 
A typical setting for surveillance bias is diagnostic work-out for a symptomatic disease leading to a fortuitous 
finding of an unrelated disease that may be asymptomatic. For example, Craig and Feinstein reviewed 43 studies 
on second primary cancers and pointed out that only 5 considered the possibility of surveillance bias1. In cancer 
screening programs detection bias leads to some degree of over-diagnosis which is tolerated because of overall 
net clinical benefits3.
The likelihood of surveillance bias has increased because diagnostic tests are more commonly used and in many 
areas of medicine imaging techniques, such as computed tomography, ultrasound and magnetic resonance imag-
ing have allowed visualisation of structures that were not seen before, for example early cancers4, 5. Urolithiasis 
(UL, urinary tract stone disease) patients are examined by computed tomography for diagnosis of kidney, ureter 
and mixed stones. Patients with bladder stones commonly receive cystoscopy and palpation of the prostate, and 
all UL patients may additionally be imagined by thorax radiography. Even if there is alertness about surveillance 
bias it may be limited by medical speciality and by risk factors for disease considered in the context of that spe-
ciality, and the full medical history of patients in terms of unrelated comorbidities may often remain unknown. 
Cancer registries provide reliable diagnostic data in countries, such as Sweden, where practically all diagnosed 
cases are reported with histological or cytological verification6. However, many cancers develop slowly, some 
within a decade or more, from a precursor lesion through an in situ stage into cancer with metastatic potential7. 
Thus diagnostic and screening procedures may find cancers at an asymptomatic stage which may be of lower 
grade than symptomatic cancer but still a histologically verified malignancy.
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The early aim of the present study was to assess the risk for urological cancers in patients who had previously 
been diagnosed with UL. UL is a common disease affecting up to 15% of population and many patients have a 
recurrent disease8, 9. UL is thought to be associated with the risk of kidney and bladder cancers, and a study from 
Taiwan’s National Health Insurance Research Database reported that UL is associated with a high risk of many 
systemic cancers in addition to urinary tract cancers10–12. Thus we considered analysing all cancer types after UL 
diagnosis. In the present study we use nation-wide Swedish hospital records of inpatients and outpatients with UL 
diagnoses and link the individual data to cancer data. We analyse the data in terms of follow-up time, proportion 
of in situ tumours and tumour size. In the course of the analyses the likelihood of detection bias became apparent, 
and the aims were shifted towards featuring some typical signs of such a bias.
Results
The total number of patients diagnosed with UL during years 1987 to 2012 was 211,718, distributed by the most 
common type, ureter stones (91,397, 43.2%), followed by kidney stones (77,972, 36.8%), mixed stones (23,890, 
11.3%) and bladder stones (18,459, 8.7%). We analysed the risk of 8 specific cancers, all other cancers together 
and all cancers combined after the last identified medical contact for the four types of UL (Table 1). All cancers 
were rather uniformly increased after kidney (SIR 1.54), ureter (1.44), mixed (1.51) and bladder stones (1.63). The 
risk of kidney cancer was increased most after kidney (3.75), ureter (2.78) and mixed stones (4.01) while bladder 
cancer was increased most after bladder stones (3.34). After bladder stones, SIRs were highest for prostate (1.74) 
and colon (1.60) cancers. Remarkably, all the listed cancers were increased in patients with kidney and ureter 
stones. Cancers at anatomically distant sites, in the lung and the breast, were increased after all types of UL, except 
for lung cancer after bladder stones.
In Table 2 cancer risk after any UL diagnosis was assessed by follow-up time since the last UL diagnosis. For all 
cancer the SIR was 4.70 during the first year (4239 cases) but then stabilised to 1.31 (12,159 cases) and 1.24 (5208 
cases) during 1–9 and 10 + years of follow-up, respectively. The initial SIRs were excessive, 22.40 and 14.02 for 
kidney and bladder cancers but they were high also for prostate (4.89) and pancreas (4.80) cancers. All but lung 
cancers were increased even at the latest follow-up time: risk for kidney cancer remained the highest (1.56) while 
non-urological cancers showed SIRs between 1.22 and 1.38.
As surveillance may lead to a shift in earlier stages we compared the proportion of in situ cancers in UL and 
all cancer patients among patients diagnosed during 2002 to 2012 because the Tumor, Node, Metastasis (TNM) 
classification was introduced in year 2002 in the Cancer Registry. We compared patients diagnosed at the age 
Cancer site
Kidney Ureter Mixed Bladder
O SIR 95% CI O SIR 95% CI O SIR 95% CI O SIR 95% CI
Colon 486 1.54 1.40 1.68 725 1.46 1.35 1.57 108 1.38 1.13 1.67 208 1.60 1.39 1.83
Pancreas 154 1.96 1.66 2.30 209 1.70 1.48 1.95 39 2.06 1.46 2.81 38 1.33 0.94 1.83
Lung 438 1.51 1.37 1.66 581 1.24 1.15 1.35 96 1.36 1.10 1.66 129 1.14 0.95 1.36
Breast 482 1.26 1.15 1.38 604 1.38 1.28 1.50 141 1.44 1.21 1.70 44 1.53 1.11 2.05
Prostate 1311 1.34 1.27 1.42 2416 1.37 1.32 1.43 331 1.30 1.16 1.45 874 1.74 1.62 1.86
Kidney 311 3.75 3.34 4.19 375 2.78 2.50 3.07 82 4.01 3.19 4.98 64 2.15 1.66 2.75
Urinary bladder 422 2.15 1.95 2.37 589 1.73 1.60 1.88 113 2.35 1.93 2.82 350 3.34 3.00 3.71
Melanoma 300 1.41 1.25 1.58 473 1.45 1.33 1.59 68 1.16 0.90 1.47 73 1.26 0.99 1.59
Other sites 2998 1.54 1.48 1.59 4223 1.42 1.38 1.46 762 1.51 1.40 1.62 986 1.41 1.33 1.51
All 6902 1.54 1.50 1.58 10195 1.44 1.42 1.47 1740 1.51 1.44 1.58 2766 1.63 1.57 1.70
Table 1. SIR for cancer of patient with urolithiasis, 1987–2012. Bold type: 95% CI does not include 1.00. 
O = observed number of cases; SIR = standardized incidence ratio; CI = confidence interval.
Follow-up (years)
<1 1–9 10+
Cancer site O SIR 95% CI O SIR 95% CI O SIR 95% CI
Colon 243 3.91 3.44 4.44 888 1.36 1.28 1.46 396 1.28 1.16 1.42
Pancreas 79 4.80 3.80 5.99 267 1.62 1.43 1.83 94 1.38 1.12 1.69
Lung 171 2.87 2.45 3.33 773 1.26 1.18 1.36 300 1.12 0.99 1.25
Breast 146 2.46 2.08 2.89 769 1.27 1.18 1.36 356 1.28 1.15 1.42
Prostate 1029 4.89 4.60 5.20 2602 1.17 1.13 1.22 1301 1.22 1.16 1.29
Kidney 400 22.40 20.26 24.70 366 1.68 1.52 1.87 112 1.56 1.29 1.88
Urinary bladder 596 14.02 12.92 15.20 614 1.39 1.28 1.50 264 1.30 1.15 1.46
Melanoma 99 2.39 1.94 2.91 556 1.32 1.21 1.43 259 1.35 1.19 1.52
Other sites 1473 3.76 3.57 3.95 5324 1.34 1.31 1.38 2126 1.22 1.17 1.28
All 4236 4.70 4.56 4.84 12159 1.31 1.29 1.33 5208 1.24 1.21 1.28
Table 2. SIR for cancer of patient with urolithiasis, 1987–2012. Bold type: 95% CI does not include 1.00. 
O = observed number of cases; SIR = standardized incidence ratio; CI = confidence interval.
www.nature.com/scientificreports/
3SCienTiFiC REpoRtS | 7: 8073  | DOI:10.1038/s41598-017-08839-5
50 + years because most UL related cancers were diagnosed in this age group. In situ cancers were reported essen-
tially only for colon and breast cancers and for melanoma. The only significant difference was for colon cancer 
for which 254/1249 (20.3%) UL related cases were in situ forms compared to 7624/42,666 (17.9%, p = 0.025) for 
all colon cancers. Tumour size migration was assessed by comparing the proportion T0 and T1 to all defined T 
classes, diagnosed during the first year after UL diagnosis. The only significant difference was for kidney can-
cer for which 106/176 (60.2%) were stages T0 + T1 of all defined T cases in UL related cancers compared to 
3353/7303 (45.9%, p =  < 0.001) in all kidney cancer.
Patients diagnosed with UL in the Hospital Discharge Register during 1987 to 1999 were followed for UL 
related visits in the Outpatient Register during 2001 to 2012. Most patients (4680, 79.2%) had no UL related visits 
in the Outpatient Register and their overall cancer risk was 1.13 (1.09–1.16); 20.8% of the patients had at least one 
visit, and their cancer risk was not increased (0.98, 0.93–1.14).
Discussion
Based on the results in Table 1 a noncritical interpretation would point out that UL is associated with cancer at 
multiple sites, even though the affected organs appeared to convey the highest risk. Considering the high preva-
lence of UL in the population, a logical conclusion should have been that UL is associated with a high population 
burden for cancer. The follow-up results in Table 2 exposed the concerns about surveillance bias, which may to 
be due to incidental clinical findings by computed tomography in diagnosis of kidney, ureter and mixed stones. 
Bladder stones are diagnosed by cystoscopy and palpation of the prostate, which may explain the high risks of 
prostate and colon cancers. All UL patients may be imagined by thorax radiography which may reveal tumours 
in the covered parts of the body.
It was somewhat surprising that the bias appeared to extend past 10 years of follow-up. The reason may be 
that in many patients UL is recurrent or at least may increase concerns leading to frequent medical contacts8, 9. 
However, using the Outpatient data to follow UL patients for multiple UL related visits, only 20.9% had one or 
more visits, suggesting that many UL patients with multiple episodes were seen in the primary care for which we 
have no data. Also the data showed that the simple number of Outpatient visits for UL causes did not appear to 
explain cancer risks because even patients with no additional visits showed an excess risk of 1.13.
The more frequent in situ diagnoses and smaller tumour sizes In UL patients compared to all cancer patients 
supported the existent of surveillance bias although the differences were modest. The mechanism of UL related 
cancer, in humans as well as in experimental animals, is believed to be mechanical wear and inflammation10–12. 
Yet it would not be self-evident that UL would cause systemic cancers because usually inflammation, for example, 
by autoimmune diseases is associated with cancers at sites affected by inflammation13–16.
Although the above data suggest involvement of surveillance bias, we need to admit that we have not elimi-
nated alternative mechanisms which predispose to UL and which might jointly predispose to cancer. Stone forma-
tion is due to a combination of genetic and environmental factors. Risk factors include high urine calcium levels, 
obesity, certain foods, some medications, calcium supplements, hyperparathyroidism, gout, diabetes, hyperten-
sion and not drinking enough fluids9. Among these obesity and diabetes are known risk factors of cancer, and 
kidney cancer, showing the highest risk in the present study, is one of the highest obesity-related cancers17–19.
Whether it is possible to eliminate surveillance bias by a study design may not be simple. A frequently applied 
method is the omission of early follow-up but this may lead to removal of true cases if these are properly diag-
nosed, such as histologically verified cancers. Comparison of cancer risk between early and late onset UL and in 
persons suffering from multiple episodes should be informative but not bias-free. We conclude that quantification 
of risks may be extremely difficult in situations when surveillance bias is likely, and scientists and readers of sci-
entific texts should be aware of such problems in observational studies.
Methods
UL patients were identified using the nationwide Swedish Hospital Discharge Register (1986–2012) and the 
Outpatient Register (2001–2012). The first UL diagnosis in either register was included and a patient was only 
entered once. Information from the registers was linked at the individual level via the national 10-digit civic reg-
istration number to the Swedish national Cancer Registry. In the linked dataset, civic registration numbers were 
replaced with serial numbers to ensure the anonymity of all individuals. Revisions 9 (1987–1996) and 10 (1997-) 
of the International Classification of Diseases (ICD) was used to identify UL diagnostic codes. Only 54,500 
patients were diagnosed during the ICD-9 period, compared to 166,600 in the ICD-10 period. Standardized 
incidence ratios (SIRs) were calculated as the ratio of observed to expected number of cases. The follow-up was 
started from the last UL diagnosis and ended at diagnosis of the first primary cancer, death (Causes of Death 
Register) or end of follow-up, December 31, 2012, whichever came first. The expected numbers were calculated 
for all individuals without a history of UL (i.e., essentially for the whole Swedish population covered by the 
Database), and the rates were standardized by 5-year-age, gender, period (5 years group), socioeconomic status 
and residential area. The 95% confidence interval (95%CI) of the SIR was calculated assuming a Poisson distribu-
tion. Data on the TNM classification were available from year 2002 onwards.
In order to assess the frequencies of medical contacts due to UL and their influence on SIRs we identified 
patients who were diagnosed with UL using the Hospital Discharge Register during 1987 to 1999 and followed 
their UL related visits from the Outpatient Register during 2001–2012.
Ethical statement. The study was approved by the Ethical Committee of Lund University and the study was 
conducted in accordance with the approved guidelines not requesting informed consent. The study is national 
register-based study on anonymous personal data.
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